Under the Public Health (Medicinal Cannabis) Act 2016 (PHMCA), a single patient prescriber is a medical specialist or general practitioner who has approval to prescribe a medicinal cannabis product to a particular patient.
To be a single-patient prescriber, you must:
- be a medical practitioner:
- either a specialist medical practitioner in the management of patients with the medical condition being treated with the product OR
- a general medical practitioner in consultation with a relevant medical specialist
- be registered (without undertakings on your registration) with the Australian Health Practitioners Regulation Agency
- have an established treating relationship with the patient, or the medical practitioner is in direct communication with another medical practitioner who has an established long-term treating relationship with the patient and both are in well-documented agreement with the application for medicinal cannabis approval for therapeutic purposes.
Guidance and regulations
- Clinical guidance for the use of medicinal cannabis products, March 2017 (PDF 492 kB): covers the medical conditions/symptoms and products to be used.
- Medicinal cannabis access and use in Queensland, March 2017 (PDF 470 kB): the process for medical practitioners to access, prescribe and supply medicinal cannabis in Queensland.
- Standard for security of medicinal cannabis stock, January 2017 (PDF 326 kB): how to secure and store medicinal cannabis products, under Part 8 of the regulation.
- Public Health (Medicinal Cannabis) Regulation 2017: describes patient-class prescribers, the class of patients to be treated, and the medicinal cannabis products to be prescribed.
Forms and templates
- Application for medicinal cannabis approval (PDF 162 kB)
- Treatment report (PDF 83 kB)
- Notification of medicinal cannabis management plan (PDF 136 kB)
- Application for approval to dispense medicinal cannabis (PDF 176 kB)
- Medicinal cannabis management plan (PDF 133 kB)
The authorised single-patient prescriber must:
- participate in product education prior to the initial administration of the product and remain up-to-date with evidence based practice (if possible or available)
- ensure the medicinal cannabis product is stored in accordance with the manufacturers specifications and meets the requirements of the security standard if they are dispensing the medication from their practice
- prepare a medicinal cannabis management plan (if they are dispensing) under the medicinal cannabis approval
- notify Queensland Health when a medicinal cannabis management plan is made, by submitting the notification form
- comply with the requirements of the medicinal cannabis approval (including but not limited to):
- not dispense medicinal cannabis for medicinal purposes to any unapproved patient.
- not exceed the approved maximum daily dose in accordance with that specified in the medicinal cannabis approval.
- not vary the approved route of administration.
- not vary the medicinal cannabis product without the relevant approvals.
- conduct a medication review prior to initiating medicinal cannabis for therapeutic purposes and in any reassessment of the patient(s) receiving medicinal cannabis.
- retain a copy of the all relevant documented approvals to prescribe medicinal cannabis in the patient’s clinical record.
- report any adverse events to the TGA and to the State, as specified in their respective regulations and/or approvals
- include processes to identify any misuse/abuse/diversion by the patient in any reassessment of patient(s) receiving cannabis for medical purposes.
- clinically reassess the patient as to the appropriateness of treatment at least once every 3 months, or more frequently if required. Compare the outcome with the stated goal of treatment to determine whether treatment with medicinal cannabis should continue
- advise the patient that if their medicinal cannabis product contains THC then they cannot drive or operate heavy machinery.
- provide a treatment report to the chief executive at 3 monthly intervals
- comply with any conditions imposed on a TGA approval relating to the medicinal cannabis product (s) being used
Other conditions may apply, depending on individual cases.